GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals re-appoints MD and Whole-time Director
MANAGEMENT ▲ Positive Development LOW RISK
📅 Filed on BSE: 13 Oct 2026, 12:23 PM IST  ·  BSE ID: f89bda37-9fcf-434a-a1d4-69171d78d1ff
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's directors have been reappointed to their top management roles for another three-year term.
🤖 AI Summary
  • Board re-appoints Mr. Swapnil Jatinbhai Shah as Managing Director for three years.
  • Mr. Chetan Bipinchandra Shah re-appointed as Whole-time Director for three years.
  • Both appointments are effective from mid-October/November 2026, subject to shareholder approval.
  • Re-appointments are based on Nomination and Remuneration Committee recommendations.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Managing Director Re-appointment Effective Date
October 15, 2026
Whole-time Director Re-appointment Effective Date
November 10, 2026
Re-appointment Term
Three (3) consecutive years
🏢 How This Affects the Company
⚙️
Operational Impact
The re-appointments ensure continuity in leadership for the company's strategic direction and day-to-day operations.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will vote on the re-appointments through a postal ballot process.
👤
Who Is Affected
All shareholders are affected as the Board has approved the continued leadership of these directors.
🔍
Management Signal
The decision signals management's intent to maintain experienced leadership continuity.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder approval outcome for re-appointments via postal ballot.
Future board meeting minutes for confirmation of appointments.
Next quarterly results for operational updates.
LOW RISK Routine re-appointment of existing directors with no new financial commitments.
💡 Investor Takeaway
Senores Pharmaceuticals' Board has re-appointed Mr. Swapnil Jatinbhai Shah as MD and Mr. Chetan Bipinchandra Shah as Whole-time Director for three-year terms, effective October 15, 2026, and November 10, 2026 respectively, pending shareholder nod.
❓ Frequently Asked Questions
Who has been re-appointed as Managing Director of Senores Pharmaceuticals?
Mr. Swapnil Jatinbhai Shah has been re-appointed as the Managing Director for a period of three years.
When is the re-appointment of Mr. Swapnil Jatinbhai Shah effective?
The re-appointment is effective from October 15, 2026, subject to shareholder approval.
Who has been re-appointed as Whole-time Director of Senores Pharmaceuticals?
Mr. Chetan Bipinchandra Shah has been re-appointed as the Whole-time Director for a period of three years.
When is the re-appointment of Mr. Chetan Bipinchandra Shah effective?
The re-appointment is effective from November 10, 2026, subject to shareholder approval.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.